Business Partnership with Metcela in Regenerative Medicine
First written in FY2022-Q3. 2 of 4 entries say "Cited as achieved", first in FY2023-Q1. Latest entry: FY2023-Q3.
No other company in this theme has enough history to compare yet.
- FY2023-Q3Cited as achievedAnnual report
「With regard to the cardiac stem cell (CSC) pipeline JRM-001, while continuing partnering activities aimed at future commercialization, the Company determined that it would be best to transfer the business to Metcela Inc., which has research and development experience and expertise in the cardiovascular field, and have that company lead development. Accordingly, on 4 April 2022, the Company resolved to transfer all shares of Nippon Regenerative Medicine Co., Ltd., its wholly owned subsidiary developing JRM-001, and completed the transfer. The Company will continue to support development activities going forward.」
The Company is reiterating, as an achievement, the transition to Metcela-led development of JRM-001 and the transfer of all shares of Nippon Regenerative Medicine. - FY2023-Q1Cited as achievedAnnual report
「With regard to the cardiac stem cell (CSC) pipeline JRM-001, while continuing partnering activities aimed at future commercialization, the Company determined that it would be best to transfer the business to Metcela Inc., which has research and development experience and expertise in the cardiovascular field, and have that company lead development. Accordingly, on 4 April 2022, the Company resolved to transfer all shares of Nippon Regenerative Medicine Co., Ltd., its wholly owned subsidiary developing JRM-001, and completed the transfer. The Company will continue to support development activities going forward.」
The Company is reiterating the transition to a system in which Metcela leads development of JRM-001 and the completed transfer of all shares of Nippon Regenerative Medicine. The Company will continue to provide development support. - FY2022AdvancedAnnual report
「As part of this arrangement, the parties reached an agreement that it would be optimal for Metcela to take the lead in developing regenerative medicine products using the CSC held by JRM in order to further grow JRM’s business. The Company therefore entered into a share transfer agreement to transfer all of its shares in JRM to Metcela.」
The business partnership with Metcela progressed to an agreement for Metcela to take the lead in developing JRM’s CSC business, followed by the execution of an agreement to transfer all JRM shares. - FY2022-Q3First statedAnnual report
「Furthermore, on 19 January 2022, the Company entered into a business partnership agreement with Metcela Inc. concerning the regenerative medicine business and commenced joint activities to accelerate development of both companies’ pipelines through the mutual provision of management resources, expertise and technology necessary for developing regenerative medicine products.」
The Company entered into a business partnership agreement with Metcela concerning the regenerative medicine business and commenced joint activities to accelerate development of both companies’ pipelines through the mutual provision of management resources, expertise and technology. The agreement date was 19 January 2022, after the end of the quarter.